Bank of New York Mellon Corp Lowers Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

Bank of New York Mellon Corp trimmed its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) by 9.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 78,859 shares of the company’s stock after selling 7,976 shares during the quarter. Bank of New York Mellon Corp’s holdings in Janux Therapeutics were worth $4,222,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Victory Capital Management Inc. increased its position in Janux Therapeutics by 143.4% in the 3rd quarter. Victory Capital Management Inc. now owns 29,745 shares of the company’s stock valued at $1,351,000 after acquiring an additional 17,525 shares during the period. Intech Investment Management LLC purchased a new position in shares of Janux Therapeutics in the 3rd quarter valued at approximately $368,000. Charles Schwab Investment Management Inc. grew its stake in shares of Janux Therapeutics by 202.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after purchasing an additional 156,675 shares during the last quarter. Algert Global LLC acquired a new position in shares of Janux Therapeutics in the third quarter valued at approximately $1,112,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Janux Therapeutics by 27.2% during the third quarter. The Manufacturers Life Insurance Company now owns 30,595 shares of the company’s stock worth $1,390,000 after purchasing an additional 6,547 shares during the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Janux Therapeutics

In related news, CEO David Alan Campbell sold 5,000 shares of Janux Therapeutics stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total transaction of $300,000.00. Following the completion of the transaction, the chief executive officer now directly owns 293,054 shares in the company, valued at $17,583,240. The trade was a 1.68 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Andrew Hollman Meyer sold 3,334 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $42.29, for a total value of $140,994.86. Following the sale, the insider now owns 82,139 shares in the company, valued at approximately $3,473,658.31. This trade represents a 3.90 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,002 shares of company stock valued at $2,684,703. Insiders own 29.40% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on JANX. Wedbush reissued an “outperform” rating and issued a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Leerink Partners lifted their target price on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. Scotiabank cut their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a report on Friday, February 28th. BTIG Research raised their price objective on shares of Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $200.00 target price on shares of Janux Therapeutics in a research report on Wednesday, December 11th. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $92.44.

Janux Therapeutics Trading Down 1.8 %

Shares of Janux Therapeutics stock opened at $30.93 on Wednesday. The company has a 50-day moving average of $38.03 and a two-hundred day moving average of $46.78. The stock has a market cap of $1.83 billion, a PE ratio of -26.44 and a beta of 3.23. Janux Therapeutics, Inc. has a 12-month low of $28.92 and a 12-month high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.